Abstract: Provided is a cured product of a resin composition including a (meth)acrylate compound and a compound having at least one thiol group, wherein the content of the compound having at least one thiol group in the cured product is 30 mass % or less, and wherein the cured product has a secondary dispersion characteristic of 0.65 or more.

Abstract: The present invention relates to the use of esters of octahydro-4,7-methano-1H-indene-5-methanol (TCD-M) or -dimethanol (TCD-DM) and aliphatic C2-C18 monocarboxylic acids as lubricants in low temperature applications. In addition, the present invention relates to low-temperature lubricant compositions comprising said esters.

Abstract: According to the present invention, as a monomer which is unlikely to be crystallized in a curable composition for manufacturing an optical member and which enables manufacture of a cured product having a high level of moisture-heat resistance, a compound represented by General Formula (A) is provided.

Abstract: An optical element including a molded article is provided, the molded article being prepared by molding a polymer prepared by polymerizing a (meth)acrylate compound represented at least by the following general formula (1): wherein a and b are each an integer of 1 or 2; X and Y are each —S— or —O—; R1 and R2 are each an alkyl group having 1 or 2 carbon atoms or a hydrogen atom; and Z1 and Z2 are each an alkyl group having 1 or 2 carbon atoms, having a substituent and represented by the following general formula (2): wherein m is selected from 0 and 1; W is a hydrogen atom or a methyl group; and V is selected from substituents represented by the following: *—O—CnH2n—O—**; *—S—CnH2n—S—**; and *—S—CnH2n—O—**, wherein * represents a bond with an alkyl group; ** represents a bond with a (meth)acryloyl group; n is selected from 2, 3 and 4; and at least one hydrogen atom of —CnH2n— is replaced by a methyl group.

Abstract: Optical films are described having a polymerized microstructured surface that comprises the reaction product of a polymerizable resin composition comprising at least one polymerizable ethylenically unsaturated triphenyl monomer. Also described are certain triphenyl (meth)acrylate monomers and polymerizable resin compositions.

Abstract: A liquid crystal composition that includes a polymerizable compound having a high solubility, a composition obtained by polymerizing the polymerizable compound in the liquid crystal composition, and an AM device including any of the compositions are described. The liquid crystal composition has negative dielectric anisotropy, and includes at least one compound selected from the group of compounds represented by formula (1): wherein P1 and P2 are polymerizable groups, and, for example, ring A and ring B are independently an adamantane ring or a noradamantane ring, Z1, Z2 and Z3 are a single bond, and a, b and c are 1.

Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.

Abstract: The present invention relates to prodrug derivatives of pentamidine, their use in the treatment and/or prophylaxis of diseases such as tumor diseases, as well as leishmaniasis, trypanosomiasis, pneumocystis carinii pneumonia (PcP), and malaria.

Abstract: The invention provides novel compounds and formulations of turmeric oil, fish oil, aspirin and anti-cancer drugs (paclitaxel) having anti-inflammatory, analgesic and/or anti-cancer activity.

Abstract: An object is to provide a liquid crystal compound having high polymerization reactivity, a high conversion ratio and high solubility in a liquid crystal composition, a polymerizable composition containing the compound, a liquid crystal composite prepared using the composition, and a liquid crystal display device having the composite. A solution is a polymerizable compound represented by formula (1). In formula (1), P1 and P2 are identically group (P-1), (P-2) or (P-3), and in formula (P-1), M is hydrogen, fluorine, —CH3 or —CF3; S1 and S2 are a single bond, alkylene having 1 to 6 carbons or the like; a1, a2 and b1 are 0, 1, 2, 3 or 4, and a sum of al and a2 is 4; ring A1 is naphthalene, anthracene or phenanthrene; and ring A2 is cyclohexyl, phenyl, naphthyl, anthracenyl or phenanthrenyl; and Z1 is a single bond, —CO—, —COO— or the like.

Abstract: The present invention relates to a polymerizable liquid crystal compound, a liquid crystal composition including the same, and an optically anisotropic body. The polymerizable liquid crystal compound according to the present invention has not only high birefringence but also excellent coating orientation, and thus it is possible to prepare a optically anisotropic body which is thin but superior in optical properties.

Abstract: The present invention provides a photosensitive monomer of which hydrogen atoms of benzene ring of a hard core are substituted by fluorine atoms to increase the electronegativity of the hard core, so that the curing voltage of the curing process is reduced. The photosensitive monomer of the present invention not only reduces the curing voltage and curing time of the curing process of liquid crystal panels, but also increases the pretilt angle of liquid crystal molecules to reduce the response time of a liquid crystal display, so that image sticking and MURA phenomenon are reduced.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

Abstract: The present invention relates to polymerizable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (“polymer sustained”) or PSA (“polymer sustained alignment”) type.

Abstract: The present invention relates to the new impurities of Fesoterodine, Fesoterodine symmetric dimer impurity and asymmetric dimer impurity, process for preparing and isolating thereof. The invention also deals with analytical standards and analytical methods used for the control of the production process and final quality of Fesoterodine.

Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays having a polymer-stabilised blue phase, and in LC media for LC displays of the PS or PSA (“polymer sustained” or “polymer sustained alignment”) type, and to LC media and LC displays comprising these compounds.

Abstract: The present invention relates to a diterpene compound derived from Aleurites fordii, and a pharmaceutical composition for treating or preventing viral infectious diseases, a health functional food for preventing or ameliorating viral infectious diseases and a composition for enhancing the production of interferon-gamma, which comprise the diterpene compound. Furthermore, the present invention relates to a method for preventing or treating viral infectious diseases including administering the composition to a subject having a viral infectious disease occurrence or a risk thereof with a therapeutically effective dose.

Abstract: The invention pertains to high-molecular photoinitiator compounds comprising a photoactive moiety Q and an amine functionality, preferably a tertiary amino group, where the photoactive moiety Q is a benzoyl photoactive moiety.

Abstract: Provided is a liquid crystal composition satisfying at least one of characteristics such as high maximum temperature of a nematic phase, low minimum temperature of the nematic phase, small viscosity, suitable optical anisotropy, large negative dielectric anisotropy, large specific resistance, high stability to ultraviolet light and high stability to heat, or having a suitable balance regarding at least two of the characteristics. Also provided is an AM device having a short response time, a large voltage holding ratio, a large contrast ratio, a long service life and so forth. The liquid crystal composition contains a specific compound having a polymerizable group as a first component, a specific compound having a large negative dielectric anisotropy and a low minimum temperature as a second component, or a specific compound having a small viscosity or a large maximum temperature as a third component, and a liquid crystal display device contains the composition.

Abstract: The present disclosure provides novel glucagon-like peptide-1 (GLP-1) receptor modulators such as compounds of Formula (I) or (II), and pharmaceutically acceptable salts thereof. The present disclosure also provides pharmaceutical compositions, kits, and uses that involve the GLP-1 receptor modulators for regulating blood glucose levels and/or treating diabetes via, e.g., modulating the endogenous signaling pathways mediated by the GLP-1 receptor.

Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays having a polymer-stabilized blue phase, and in LC media for LC displays of the PS or PSA (“polymer sustained” or “polymer sustained alignment”) type, and to LC media and LC displays comprising these compounds.

Abstract: Compounds having a structure of Structure I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein R1, R2, R3, R4, R5, J1, J2, X, Z, n1 and n2 are as defined herein, and wherein at least one of R1, R2 or R3 is an alkyl, alkenyl, aryl or aralkyl ester, are provided. Uses of such compounds for treatment of various indications, including prostate cancer, as well as methods of treatment involving such compounds are also provided.

Abstract: The invention relates to a dental restorative material which comprises a thermolabile or photolabile polymerizable compound of Formula I: [(Z1)m-Q1-X)]k-T-[Y-Q2-(Z2)n]1??Formula I, in which T represents a thermolabile or photolabile group, Z1 and Z2 in each case independently represent a polymerizable group selected from vinyl groups, CH2?CR1—CO—O— and CH2?CR1—CO—NR2— or an adhesive group selected from —Si(OR)3, —COOH, —O—PO(OH)2, —PO(OH)2, —SO2OH and —SH, wherein at least one Z1 or Z2 is a polymerizable group, Q1 in each case independently is missing or represents an (m+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, Q2 in each case independently is missing or represents an (n+1)-valent linear or branched aliphatic C1-C20 radical which can be interrupted by —O—, —S—, —CO—O—, —O—CO—, —CO—NR3—, —NR3—CO—, —O—CO—NR3—, —NR3—CO—O— or —NR3—CO—NR3—, X and Y in each case independently are missing

Abstract: A cyclic compound of the present invention has a molecular weight of 500 to 5000, and is represented by the following formula (1):

Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.

Abstract: Described is a resinous article of manufacture that is wrinkle-resistant and is warpage-resistant when subjected to very high temperatures. Such an article is useful as an optical lens.

Abstract: The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.

Abstract: A polymer for resist use is obtainable from a monomer having formula (1) wherein R1 is H, CH3 or CF3, R2 and R3 are a monovalent hydrocarbon group, R4 to R9 are hydrogen or a monovalent hydrocarbon group, R10 is a monovalent hydrocarbon group or fluorinated hydrocarbon group, A1 is a divalent hydrocarbon group, k1 is 0 or 1, and n1A is 0, 1 or 2. A resist composition comprising the polymer displays a high dissolution contrast during organic solvent development.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.

Abstract: This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, CNS, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins. It inhibits excess adhesion and inhibits cell attachment. It modulates angiogenesis. The compounds also use as mediator of cell adhesion receptor, cell circulating, cell moving and inflammatory diseases.

Abstract: Statin compositions are disclosed for stimulating neurite growth from spiral ganglion neurons in the inner ear and methods for preventing damage to or treating damage of auditory neurons and/or hair cells of the cochlea following acoustic or toxic insult.

Abstract: One aspect of the disclosure relates to derivatives of aryl and heterocyclic ureido aryl and heterocyclic carboxamido isobutyric acids, dichlorophenyl urea, curcumin, and 1,3-diazetidine-2,4-dione, and pharmaceutical compositions thereof. The derivatives disclosed herein can modulate development of adipocytes and various cancer cells, including resistant cancer cells and cancer stem cells. Another aspect of the disclosure relates to the use of the derivatives and pharmaceutical compositions disclosed herein in treatment of obesity and various cancers.

Abstract: The present invention relates to an acrylate-based compound that includes an organic acid having two or more acrylate groups and one or more phenolic acid structures in one molecule, and a photosensitive composition including the same. It is possible to shorten a developing time in a photolithography process without damaging photosensitivity by using the photosensitive composition according to the present invention.

Abstract: A composition including one or more ester resins useful for various applications is disclosed. For example, the composition including one or more ester resins may function as a component that is incorporated into an ink composition.

Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, to liquid-crystal (LC) media comprising them, and to the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the PSA (“polymer sustained alignment”) type.

Abstract: The present invention provides a photosensitive monomer, a liquid crystal composition containing the photosensitive monomer and a vertical alignment liquid crystal panel. The range of absorption wavelength of the photosensitive monomer of the present invention overlaps with the range of an ultraviolet lamp by increasing the length of a hard core. Thus, comparing with the conventional reactive monomer (RM), the photosensitive monomer of the present invention has a faster curing speed to solve the image sticking issue due to a high monomer residue.

Abstract: The present invention relates to polymerizable compounds, liquid-crystalline media containing the compounds, in particular liquid crystal (LC) media and LC displays having a polymer-stabilized blue phase, and also LC media for LC displays of the PS or PSA type (“polymer-sustained” or “polymer-sustained alignment”).

Abstract: The present invention relates to polymerisable compounds, to processes and intermediates for the preparation thereof, and to the use thereof for optical, electro-optical and electronic purposes, in particular in liquid-crystal (LC) media and LC displays, especially in LC displays of the PS (polymer-stabilised) and PSA (polymer-sustained alignment) type.

Abstract: Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.

Abstract: The instant invention relates to mesogenic media comprising one or more compounds selected from the group of compounds of formulae I to XA wherein the parameters are as specified in the text, preferably to mesogenic media showing a blue phase, preferably stabilised by a polymer, and their use in electro-optical light modulation elements and their respective use in displays, as well as to such devices.

Abstract: Chelating monomers and fluoride-releasing compositions are disclosed that may be incorporated into dental composite restorative materials, dental bonding agents or other dental materials, to produce materials with high fluoride release rates, and high fluoride recharge capability. Such dental restorative materials may help reduce the level of dental caries in patients, particularly the level of caries occurring on the margins of the restorative materials.

Abstract: A polymerizable monomer adopted to a display panel is represented as following chemical formula: wherein, m?0; “Z” is selected from oxygen, sulfur, carbonyl, caroboxyl, methyoxy, methylthio, thio, ethenylcarbonyl, carbonylethenyl, difluoromethoxy, difluoro methylthio, ethyl, difluoroethane, 1,2 difluoroethane, vinylene, difluoroethenylene, ethynyl, or single bond. “X1” and “X2” are independently selected from oxygen, sulfur, methyoxy, carbonyl, caroboxyl, -carbamoyl, methylthio, ethenylcarbonyl, carbonylethenyl, or single bond. “Sp1” and “Sp2” are independently a spacer or single bond. “P1” and “P2” are independently a polymerizable group.

Abstract: The compound represented by formula (1). For example, the rings A1, A2, A3 and A4 are 1,4-phenylene, Z1 and Z2 are alkylene having 1 to 10 carbons in which at least one —CH2— may be replaced by —O— or —CH?CH—; L1, L2 and L3 are a single bond, —COO— or —CH?CH—; G1 and G2 area single bond or —O—; s, t and u are 0 or 1; and P1 and P2 is the group (P-1), the group (P-2) or the group (P-3). M1 and M2 are hydrogen or methyl.

Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment and prevention of stroke and the sequelae of stroke. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools to treat or prevent stroke and the long term effects of stroke in mammalian subjects.

Abstract: An object of the present invention is to provide a radically curable compound which produces cured products with excellent heat resistance, and in order to achieve the object, the present invention provides a radically curable compound represented by general formula (1) below. (In the formula, R1 and R2 are each independently an alkyl group having 1 to 8 carbon atoms, R3 and R4 are each independently a hydrogen atom or a methyl group, m and n are each independently an integer of 1 to 4, and X is an aromatic hydrocarbon group or an aromatic hydrocarbon group substituted by an alkyl group having 1 to 8 carbon atoms.

Abstract: A composition for forming an insulating material used in electronic devices which includes, as a polymerizable component, a monomer comprising two or more (meth)acrylic moieties and a polycyclic alicyclic structure.

Abstract: The present invention relates to new diterpenoid derivatives of formula (I), processes for their preparation, and to pharmaceutical compositions containing them for the treatment of cardiovascular disorders, urinary incontinence, asthma, or Alzheimer's disease and/or to prevent obstructive vascular lesions consequently to arteriotomy and/or angioplasty, and to prevent organ damage in hypertensive patients.

Abstract: The invention relates to novel curcumin and tetrahydrocurcumin derivatives, which have been modified at one phenolic group to incorporate more-reactive groups. The curcumin and tetrahydrocurcumin derivatives are in the form of monomers, dimmers, and polymers.

Abstract: A compound represented by formula (1), a liquid crystal composition, a liquid crystal display device are described. In formula (1), for example, the ring A1 and the ring A4 are phenylene or cyclohexylene; Z1, Z2, Z3 and Z4 are a single bond or alkylene having 1 to 6 carbons; L1 is a single bond; s and t are 0; and P1, P2, P3 and P4 are a polymerizable group.

Abstract: The disclosure relates to cannabinoid derivative compounds, pharmaceutical compositions made thereof, and methods for treating various diseases and disorders including cancer.